In the evolving landscape of financial regulation, broker-dealers face mounting pressure to fortify their anti-money laundering (AML) frameworks, particularly in trade surveillance. FINRA Regulatory Notice 21-03, issued on February 10, 2021, underscores the heightened risks associated with low-priced securities—often referred to as microcap or penny stocks—and the need for vigilant monitoring to detect potential fraud and market manipulations.
These securities, characterized by volatility, low trading volumes, and limited transparency, have long been fertile ground for illicit activities, including pump-and-dump schemes and misrepresentations tied to high-profile events like COVID-19-related products.
The notice emphasizes broker-dealers’ role as gatekeepers, urging firms to integrate AML reviews with robust trade surveillance systems to identify red flags such as unusual trading patterns, mismatched disclosures, or coordinated activities. This cohesive approach is not merely advisory; failures can lead to significant regulatory scrutiny, as evidenced by disciplinary actions against platforms like OTC Markets.
For departments handling investment banking, market making, and research, the implications are profound:siloed operations risk overlooking interconnected risks, potentially exposing firms to fines, reputational damage, and operational disruptions. This article explores the core tenets of Notice 21-03, its ripple effects across key broker-dealer functions, and real-world lessons from enforcement actions, advocating for a unified AML strategy to safeguard market integrity.
Understanding FINRA Regulatory Notice 21-03:
Regulatory Notice 21-03 highlights the persistent vulnerabilities in low-priced securities markets, where bad actors exploit information asymmetries to manipulate prices and launder funds. The notice identifies common red flags, including:
- Sudden spikes in trading volume or price without corresponding news or fundamentals.
- Coordinated buying/selling across related accounts.
- Misrepresentations about issuer involvement in trending sectors (e.g., biotech or PPE during the pandemic).
- Use of offshore entities or omnibus accounts to obscure beneficial ownership.
These indicators often overlap with broader AML concerns outlined in FINRA Notice 19-18, such as suspicious activity reporting (SAR) thresholds and customer due diligence. Broker-dealers must conduct reasonable inquiries under Section 5 of the Securities Act and adhere to FINRA Rules 2010 (Standards of Commercial Honor), 2020 (Manipulative Devices), and 3110 (Supervision) to mitigate liability.
At its heart, the notice demands cohesive AML review—an integrated process where trade surveillance feeds directly into AML workflows. Fragmented systems, where trading desks operate independently of compliance teams, can miss layered risks, such as layering or wash trades in thinly traded OTC equities. Firms are encouraged to leverage tools like automated alerts, exception reports, and cross-departmental escalation protocols to ensure timely SAR filings (required for transactions over $5,000 involving unidentified suspects).
Lessons from Enforcement: OTC Markets Disciplinary Actions
Real-world cases illustrate the perils of disjointed surveillance. In August 2024, the SEC charged OTC Link LLC (an ATS for OTC securities) with failing to implement AML surveillance, missing red flags like spoofing and wash trading in microcaps from March 2020 through May 2023, resulting in unreported SARs. The firm agreed to pay a $1.19 million penalty, highlighting the need for reasonably designed AML policies to monitor suspicious transactions.
FINRA paralleled this with actions against broker-dealers using OTC platforms. For example, in April 2024, FINRA fined Goldman Sachs & Co. LLC $512,500 for failing to include certain OTC equity securities in its automated surveillance reports designed to detect potentially manipulative trading, leading to missed alerts and inadequate supervisory reviews.
Similarly, in August 2023, the SEC charged Archipelago Trading Services Inc. (ATSI), operator of the Global OTC ATS, with years of absent AML programs, allowing thousands of daily microcap trades to evade detection for suspicious manipulative activity. These cases, tied to Notice 21-03’s fraud alerts, emphasize that OTC’s limited oversight demands broker-dealers to proactively surveil via integrated systems, lest they face expulsion or bars.
Conclusion: Toward a Unified AML Framework
FINRA Regulatory Notice 21-03 is a clarion call for broker-dealers to weave AML into the fabric of trade surveillance, particularly amid OTC Markets’ opaque dynamics. For investment banking, market making, and research, this means breaking down silos: shared data feeds, joint training, and firm-wide testing to catch red flags early.
Firms should audit current systems against the notice’s guidance, incorporating OTC compliance feeds and $5,000 SAR thresholds. As enforcement trends show—from OTC Link and ATSI failures—the price of inaction is steep. By fostering cohesion, broker-dealers not only comply but fortify investor trust, ensuring vibrant markets free from manipulation’s shadow. As of October 2025, with FINRA’s 2025 Oversight Report reaffirming microcap priorities and referencing Notice 21-03 in AML and manipulative trading contexts, the time for integrated AML is now.
The MCG Team stands ready to assist your Firm, reach out to info@mcgcomply.com
